Search

everythinglearnresearchcommunity

for

Search:↓

Kintor is starting a phase III trial for KX-826 combined with minoxidil for hair loss. Opinions vary on the potential success of the treatment, with some skepticism expressed.

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. UC Irvine scientists discover possible baldness cure.

A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.

A user on finasteride for 7+ months shared bloodwork results, questioning if high DHT levels and testosterone could affect cholesterol. Replies suggest consulting a doctor and question the high testosterone levels.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

Ultrasound imaging can non-invasively detect active and inactive hair follicles, inflammation, and fibrosis, potentially reducing unnecessary biopsies. It may help assess hair growth potential and diagnose scalp issues, but some users believe in trying treatments regardless of ultrasound results.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The conversation discusses whether creatine is safe to use with finasteride for hair loss treatment. It suggests consulting a doctor before adjusting finasteride dosage.

The user started taking 0.25mg finasteride daily on 9/19/25, along with using 2% ketoconazole, rosemary oil, and dermastamping. They are hesitant to add minoxidil due to heart palpitations.

Creatine may increase DHT levels, potentially affecting hair loss, but evidence is mostly anecdotal. A study to explore this was withdrawn due to funding issues.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

The post discusses the use of El-Cranell, which contains Alfatradiol, and Quercetin as a treatment for hair loss. The user is seeking recommendations on the amount of Quercetin to add to the solution. The conclusion of the document is that Quercetin has been shown to stimulate hair growth and inhibit DHT, and combining it with zinc/copper may have a synergistic effect.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

The study on creatine monohydrate's effect on hair loss was withdrawn due to lack of support. Users discussed concerns about creatine potentially accelerating hair loss, especially for those using finasteride.

The conversation discusses a user's plan to inject NAD+ and GHK-Cu into their scalp to improve hair health, with concerns raised about the risks of infection and necrosis. Alternatives like finasteride, dutasteride, microneedling, oral minoxidil, and scalp massages are suggested.

The user has mostly recovered hair density using finasteride, alternating oral and topical minoxidil, and occasional dermarolling, but the crown area is still struggling. Advice includes continuing treatment for up to 24 months and possibly consulting a doctor if issues persist.

Resveratrol may impair exercise benefits and isn't popular for heart health. Quercetin might reduce hair greying, while NMN is relatively new with limited information.

User experienced reduced hair loss with 15mg RU in Serioxyl but had concerning chest pain. Others suggested consulting a doctor or lowering the dose.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

Clascoterone (CB) shows an excellent safety profile with no serious side effects, but its effectiveness may decline after six months, making it more suitable as an adjunct treatment with finasteride and minoxidil rather than a standalone solution. Some argue it could be better than finasteride due to its protection against testosterone, but its long-term efficacy remains debated.

The user has been using oral finasteride for over a year and recently added GHK-CU for two months, seeing progress but seeking further improvement, especially on the hairline. They discuss sourcing GHK-CU, its effects, and the importance of third-party testing, while considering additional treatments like dutasteride and hair transplants for better results.

The user experimented with finasteride to reduce hair loss and plans to test if creatine affects DHT levels while on finasteride. Initial results showed low DHT levels, indicating finasteride's effectiveness, with further tests planned for creatine's impact.

OP noticed fuller and thicker hair after almost 4 months of using GHK-Cu, a copper-binding peptide, through subcutaneous injections. Some users were skeptical, questioning the authenticity and potential commercial intent behind the post.

Finasteride and Nizoral shampoo with Ketoconazole are used for hair loss treatment. Liquid Chromatography–Mass Spectrometry (LC-MS) is recommended over Enzyme-Linked Immunosorbent Assay (ELISA) for more accurate DHT testing.

Finasteride can affect hormone levels within two weeks, and a break of several weeks is recommended for baseline results. Monitoring E2 and testosterone is suggested to assess the risk of gynecomastia.